康方生物旗下明星药物依沃西单抗又在头对头试验中胜出了。4月23日,港股上市公司康方生物发布公告,双抗药物依沃西单抗(PD-1/VEGF双抗)联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的Ⅲ期头对头临床试验,显示强阳性结果。依沃西单抗此前还曾在与帕博利珠单抗(Keytruda,俗称K药)对比治疗局部晚期或转移性非小细胞肺癌的注册性Ⅲ期临床试验研究数据中展现出更高的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.